Therapeutic peptides and aging: how a 2026 review sorted the field
A Frontiers in Aging narrative review put approved incretin drugs and unapproved research peptides on the same table — and the evidence gap is the point.
A January 2026 narrative review in *Frontiers in Aging* surveyed peptides discussed for “healthy aging,” from tirzepatide to epitalon, GHK-Cu, BPC-157, TB-500, Semax, CJC-1295 and ipamorelin.
The useful distinction
The paper’s table makes a blunt split. Some agents (incretin receptor agonists) have large randomized trials and approved indications. Others have animal data, Phase I safety, or no efficacy RCTs, and several are WADA-prohibited. Treating that whole list as one “longevity peptide” category is a marketing habit, not a scientific one.
What readers should take
If a compound has outcome trials in a disease, read those trials. If it has only rodent healing models, say so. The 2026 review is valuable as a map of claims versus trial status, not as a shopping list.
Bottom line
Evidence ladder: mixed — Human RCT for some metabolic peptides, Animal or Human pilot for most research-chemical names. Grade each peptide, not the hashtag.
Sources
Educational content only — not medical advice. See our Medical disclaimer and Editorial policy.